Arsenal Capital Partners has appointed David Spaight as an operating partner for the firm’s healthcare group. Previously, Spaight was chairman and CEO of WIL Research Company.
NEW YORK, October 17, 2016 — Arsenal Capital Partners, a leading New York based private equity firm that invests in middle market healthcare and specialty industrial companies, announced today that it has expanded its team with the addition of David Spaight. Mr. Spaight will work as an Operating Partner within the firm’s Healthcare Group.
Mr. Spaight was most recently Chairman and Chief Executive Officer of WIL Research Company, where he led the successful turnaround of the global contract research organization focused on preclinical R&D and contract development and manufacturing services. In April 2016, Mr. Spaight led the $585 million sale of WIL Research to Charles River Laboratories (NYSE: CRL). Prior to joining WIL Research in 2010, Mr. Spaight held numerous senior executive positions at leading biopharma services and life sciences companies, such as MDS Pharma Services, ThermoFisher (NYSE: TMO), and PerkinElmer (NYSE: PKI). Mr. Spaight received his MBA from Stephen M. Ross School of Business at the University of Michigan and his B.S. in Chemistry from the University of Michigan.
Stephen McLean, Arsenal Partner and co-Head of Arsenal’s Healthcare Group said, “Arsenal has an established track record of building world-class businesses that drive process improvements in key sectors of healthcare. In particular, we have made a number of investments in businesses that help improve the safety and productivity of pharmaceutical and biotechnology research and development. We are confident David will make a major contribution to this important mission.”
Dr. Donald Deieso, Arsenal Operating Partner and co-Head of Arsenal’s Healthcare Group commented, “We welcome David to our team. David’s career has been characterized by 30 years of innovative executive leadership experience in biopharma services and life sciences. We are delighted to have him bring his unique set of skills to help guide the growth and impact of our portfolio companies.”
Mr. Spaight stated, “This is a uniquely exciting and important time to be working within the Healthcare Industry. Significant opportunities exist to improve the efficacy of patient care by improving the workflow of pharmaceutical research and development and provider operations. Our team and our Arsenal portfolio companies are committed to this important work. I joined Arsenal with a shared enthusiasm for these endeavors.”
Arsenal just completed fundraising for its latest fund, Arsenal Capital Fund IV, reaching its hard cap of $1.3 billion of committed capital.
About Arsenal Capital Partners
Arsenal Capital Partners is a leading New York based private equity firm established in 2000 that invests in middle market healthcare and specialty industrial companies. Since inception, Arsenal has raised institutional equity investment funds totaling $2.975 billion. Arsenal makes investments in growth companies in sectors in which the firm has significant prior knowledge and experience. Within its healthcare portfolio, Arsenal targets businesses that have the potential for further value creation, and works closely with management to accelerate growth by leveraging the firm’s industry focus and operational improvement capabilities. For additional information on Arsenal Capital Partners, please visit www.arsenalcapital.com.